Venus Medtech’s Post

💜 Eight-year follow-up data of VenusP-Valve impresses at OCC-WCC 2024! 💛 At the 18th Oriental Congress of Cardiology Together with the World Congress of Cardiology (OCC-WCC 2024), Prof. Zhou Daxin from Zhongshan Hospital affiliated to Fudan University, presented the eight-year follow-up data from the China pivotal clinical trial of VenusP-Valve, a transcatheter pulmonic valve replacement (TPVR) system. 🔝 Top Takeaways: Long-term Safety: No increase in cardiac deaths at eight-year compared to one, three, five, and seven years post-procedure; Long-term Efficacy: Good valve function, improved hemodynamics, and sustained patient benefits backed by eight-year post-procedural results; Improved Quality of Life: Six female subjects became mothers during the follow-up period. Following its first clinical implantation in 2013, VenusP-Valve has been applied in clinical practice for 11 years. In June 2024, VenusP-Valve completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine. #TPVR#Pulmonary# Pulmonary regurgitation#CHD#structural heart#VenusP-Valve#OCC#WCC#PROTEUS#IDE#

  • No alternative text description for this image
  • No alternative text description for this image
  • No alternative text description for this image
  • No alternative text description for this image
Marcelo Damián Rivarola

Cardiólogo intervencionista en Cardiopatías Congénitas Proctor for Venus P-Valve and Vitae valve

5mo

Great news for the patients who received the implants and best news for the large number of patients who need a pulmonary valve!!!

Like
Reply
Hitesh Tailor

Business Development at BVM Medical

5mo

Congratulations!!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics